Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Advances In™ Hematology: How Can We Translate Recent Evidence Into the Clinical Management of High-Risk MDS?

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

Accurate and rapid diagnosis and classification of myelodysplastic syndromes (MDS) subtype is critical to initiate effective treatment for patients who are at high risk of disease progression. Risk stratification systems enable clinicians to categorize the level of risk for each patient and further determine best therapeutic options for patients with high-risk MDS. It is paramount that healthcare providers remain current in their knowledge of clinical data that support or refute therapeutic options that are US Food and Drug Administration (FDA)‒approved or in clinical development. Recent reports from clinical trial data offer potential for changes to the treatment of high-risk MDS that need to be incorporated into the decision-making process, as well as into strategies for management of anemia and low platelet count. It is also extremely important that clinicians who treat patients with MDS are aware of ongoing clinical trials to refer patients for enrollment, when appropriate, for the best clinical outcomes.

This Advances In: Hematology program will help clinicians meet the challenge of acquiring this knowledge by featuring a series of video interviews with top experts in MDS addressing making an accurate diagnosis of MDS, best practices in risk stratification of patients with MDS, and how clinical challenges that are commonly observed can be overcome in patients with high-risk MDS, as well as reviewing novel therapeutic options for this high-risk patient population.

Benefits of Participating

  • Increase knowledge and competence regarding diagnostic and prognostic assessment of MDS
  • Learn strategies to effectively manage complex cases of high-risk MDS within the context of best practice
  • Utilize complex high-risk MDS case examples provided by experts to support effective clinical decision-making in your practice
  • Build confidence in your knowledge of how to optimally treat various MDS subsets with novel therapeutic strategies and agents
  • Improve knowledge of best practice management of patients after treatment failure

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This activity is intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with MDS. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of MDS are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe the current categorization of MDS disease and how risk stratification impacts clinical decision-making
  • Summarize evidence-based diagnostic and therapeutic strategies for the treatment of MDS
  • Assess how individual patient characteristics can impact outcomes in MDS, including response to therapies, survival, or progression to AML
  • Define the role of new and emerging therapies and their clinical applications to the future of MDS management

Faculty, Staff, and Planners’ Disclosures


Michael R. Savona
Michael R. Savona, MD
Director of Hematology Research
Director, Hematology Early Therapeutics Program
Professor of Medicine (Hematology/Oncology)
Vanderbilt-Ingram Cancer Center
Vanderbilt University School of Medicine
Nashville, TN

Disclosures: Grant/Research Support: Astex, Incyte, Takeda, TG Therapeutics; Consultant: Astex, Celgene, TG Therapeutics; Shareholder: Karyopharm Therapeutics.

Pinkal Desai
Pinkal Desai, MD, MPH
Assistant Professor of Medicine
Charles, Lillian, and Betty Neuwirth Clinical Scholar in Oncology
Leukemia Program
Weill Cornell Medicine

Disclosures: Grant Research Support: Astex; Consultant: Sanofi, Celgene, Astellas.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By